Glenmark Pharmaceuticals

Tata Motors, Petronet LNG, Apollo Hospitals, IRCTC among companies set to announce Q1FY27 results today.

Glenmark Pharmaceuticals on Friday reported a multi-fold increase in consolidated profit after tax at Rs 482.83 crore in the first quarter ended June 30, 2026, on the back of strong revenue growth and low base effect. The company had posted a consolidated profit after tax (PAT) of Rs 46.97 crore in the corresponding quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing. In the year-ago quarter, the company had an exceptional item outgo of Rs 323.23 crore. Consolidated total revenue from operations in the first quarter this fiscal stood at Rs 4,018.48 crore as compared to Rs 3,264.44 crore in the same period a year ago, the filing said. Total expenses in the quarter under review were higher at Rs 3,440.86 crore as compared to Rs 2,872.07 crore, the company said. "We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. "India continued to outperform the market, North America delivered

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Glenmark Pharmaceuticals on Monday announced the launch of the generic version of Olanzapine injection, indicated for treatment of schizophrenia and bipolar disorder, in the US. The company's arm Glenmark Pharmaceuticals Inc, USA has launched Olanzapine for injection of strength 10 mg/vial, single-dose vial, Glenmark said in a regulatory filing. The company's Olanzapine for injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa intramuscular injection 10 mg/vial, of Cheplapharm Registration GmbH, it added. "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12-month period ended May 2026, Glenmark said the Zyprexa intramuscular injection market achieved annual sales of approximately USD 25.4 million.

Company's Lacosamide Injection, available in single-dose vials, is a generic version of UCB's Vimpat; reference drug recorded annual sales of $15.2 million

Stocks to Watch today, May 21, 2026: Bosch, Whirlpool of India, Aditya Birla Capital, and Reliance Industries are some of the key stocks to watch today

Stocks to buy: Ajit Mishra of Religare Broking recommends buying the shares of State Bank of India, Glenmark Pharma, and Tata Power today

Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic version of progesterone vaginal inserts used in fertility treatments. The approval by the US Food and Drug Administration (USFDA) is for progesterone vaginal inserts of strength 100 mg, Glenmark Pharmaceuticals Ltd said in a regulatory filing. It has been determined by the USFDA to be bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin vaginal inserts, 100 mg of Ferring Pharmaceuticals Inc, it added. Glenmark's progesterone vaginal inserts 100 mg will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, the company said. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12 months ended February ..

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Glenmark will directly manage Ryaltris sales in the US from April 2026, strengthening its innovation-led portfolio and expanding its commercial presence in the market

Ajit Mishra of Religare Broking recommends buying the shares of BSE, Delhivery, and Glenmark Pharmaceuticals today; check all the key details here

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management following the molecule behind products like Ozempic and Wegovy going off patent in India. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk. Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in t

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Ajit Mishra of Religare Broking recommended Glenmark Pharmaceuticals, TVS Motor Company, and Power Finance Corporation for Thursday's session

The NSE to levy 15% additional margin on equity derivatives in which top 10 clients account for more than 20% MWPL from March F&O series onwards; withdraws additional margin on Gold, Silver futures.

Pharma major reports double-digit growth in Q3 as India and North America lead performance, though profit and revenue declined sequentially

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

The company informed exchanges that it has received the EIR from the US FDA for its formulations manufacturing facility in Monroe, North Carolina, with a Voluntary Action Indicated (VAI) status

Stocks to buy: Ajit Mishra of Religare Broking recommends buying Axis Bank, Glenmark Pharma, and United Spirits; also suggests Nifty trading strategy

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)